JUNS (Jupiter Neurosciences Inc) מכפיל EV/EBITDA

The share price of Jupiter Neurosciences Inc (JUNS) visualized below on GURU.Markets, where the EV/EBITDA ratio stands at 0.00, highlights the risks of limited capital and the uncertainty surrounding Alzheimer's drug trials. Jupiter Neurosciences Inc is focused on developing JPC-033, an enhanced resveratrol designed to combat neuronal decay. However, the business faces skepticism from regulatory bodies regarding plant-based formulas and intense pressure from traditional pharmaceutical behemoths.
פילוחי מדדים מקיפים ואנליטיקה עבור Jupiter Neurosciences, Inc. (JUNS)

The EV/EBITDA multiple determines the total value of a business relative to its operating profit before depreciation and amortization, allowing for an assessment of company efficiency regardless of debt load or tax regime. By analyzing the historical EV/EBITDA chart for Jupiter Neurosciences Inc. (JUNS), an investor can track the impact of drug delivery system development costs and production diversification on the enterprise's overall capitalization.